Fussen Pharmaceutical (01652) announced results for the year ended December 31, 2023, and the group made profits during the period...
According to the Zhitong Finance App, Fussen Pharmaceutical (01652) announced the results for the year ended December 31, 2023. The group achieved revenue of 566 million yuan (RMB, same below) during the period, an increase of 15% over the previous year; the loss due to the company's equity holders was 36.277 million yuan, an increase of 4.83% over the previous year; and the basic loss per share was 5 points.
According to the announcement, the increase in the Group's revenue is not only due to traditional self-operated anti-cold and fever drugs, but the revenue and share of new saleable products also continues to increase.